@GoldenMindTrade
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Impatient to the patient my friend. Im not complaining.
Did half of what we did in 2016 in last quarter alone :)
Found this, and thought it was interesting
http://www.businesswire.com/news/home/20170630005691/en/Global-Autologous-Cell-Therapy-Market-Grow-CAGR
"There has been an increased demand for providing effective drugs for cardiac and degenerative disorders globally. Prior to the advent of autologous cell therapies, there was no effective drug to repair a damaged heart. The discovery of possible cardiac autologous cells opened new possibilities for repairing damaged cardiac tissue caused by acute myocardial infarction or coronary artery disease.
There are approximately 19 product candidates being developed for the treatment of cardiac disorders, with eight in Phase III and six in Phase II development stages. Some of the companies that are developing these drugs include Shire, Athersys, Japan Regenerative Medicine, MyoCell, and Celyad. These products are expected to be launched during the forecast period and will have a substantial impact on the market growth."
I'm here for good. Thanks all :) revs will be coming in around 10 mil a year for 2018 at this rate of growth. Its only a matter of time before more private equity money comes pouring in to open more clinics and to fund their trials.
FDA comment on 21st century cures act from August 8th
"These findings are particularly relevant in light of the 21st Century Cures Act implemented last December, which aims to speed up the drug approval process through several new or expanded pathways. According to the study authors, this has led to concerns that expedited review will become the rule rather than the exception for new drugs."
http://www.ajmc.com/newsroom/drugs-receiving-fda-expedited-review-produce-greater-health-benefits-study-finds
&
Senate passes right to try law last week.
https://www.bioedge.org/bioethics/us-senate-passes-right-to-try-law/12383
Over 1000 people at the RAAD Festival. Im guessing a few hundred saw Kristin. Did anyone go?
I was hoping for a pullback. Damn it.
Dont worry about what others say just try and see the trends
Kristen and Mike are still on the board. Email the CEO.
Another 5 clinics about to generate more more more revs for Q3!
Done, looking forward to when this thing corrects itself with a proper valuation.
Cash Flow will continue to grow along with revenues, profits, and assets as a whole. Financials say it all. I am not focused on ownership of anything I am focused on sustainable growth and a revenue streams continuing to grow and expand, which is happening. Very undervalued here can't wait for big money to jump in. I like where Tomas is going.
From last 10Q
Lab and Medical Equipment Capitalized Lease
On March 3, 2017, the Company entered into an asset sale and lease agreement (sale/leaseback transaction; “ Asset Sale and Lease Agreement” ), whereby the Company sold certain lab, medical and other equipment relating to the cell banking business for $400,000 and leased back the sold equipment over a three year term. The Company recorded the equipment and the capitalized lease liability at the estimated present value of the minimum lease payments of $619,825. This amount was reduced for lease payments made of $94,428 and increased by $253,309 as of June 30, 2017 due to the increase in the effective interest rate from 75.73% to 112.16% resulting in an estimated present value of minimum lease payment of $778,706 as of June 30, 2017. The $233,309 adjustment was recorded as an increase of non-cash interest expense.
The lease includes a base monthly rental payment of $20,000, due the first day of each calendar month. In addition, the Company is required to pay 2.3%, 22.5%, and 31.6% of revenues collected on deposits arising from cell banking business for years 1, 2 and 3, respectively. At the expiration of the lease, the Company is required to return all leased equipment and along with any maintenance records, logs, etc. in the Company’s possession to the lessor with no right of repurchase.
Seems we will start to see substantial increase in revs from cell banking going from 2.3% to 22.5% in year 2.
Balance sheet and P&L continue to strengthen while revs continue to grow faster as clinics are expanding.
Investing Activities
Net cash provided by investing activities was $640,000 for the six months ended June 30, 2017 represented proceeds from our equity investment of $140,000, $400,000 from sale of property and equipment and $100,000 receipt of deposit for the sale of our intellectual property and customers as compared to cash provided by investing activities of $65,000 from our equity investments and $500 from sale of property and equipment for the same period last year.
Imagine more clinics opened by year's end, and doing $2mil a quarter. I don't think $12 mil valuation is fair at all. Looking for some curveball news no one sees coming.
Its a fake wall if you ask me, Itll get gobbled up. Too much going on here
Bought some more thanks everyone
She is on the schedule to present August 12, this Saturday http://raadfest.com/schedule2017/
Solid stem cell therapy growth through 2025
https://www.medgadget.com/2017/08/stem-cell-therapy-market-size-share-to-see-modest-growth-through-2025.html
Thanks everyone, thought a good depiction was needed. I still didn't say of half the good stuff going on here, but now people at least have somewhere to start.
Goodluck all,
Don't you love it, that's why Kristin was with Ortiz in the photo in the SCOE in Miami :), Growth growing and with politics changing. Just seems money will be pouring into this industry. Can't argue with the numbers $USRM is producing
Ill buy this till I cant. Only way this turns out bad is if gov comes in and shuts down which I don't see happening. Nice try everyone. Any start up with revs like this would be gobbled up at a 20x multiple minimum.
US STEM CELL UPDATE 8/8/2017 8:14:40 pm Eastern
$USRM continues to lead the industry in regenerative medicine therapy procedures and revenues continue to grow. Last Quarter revs were up to $601k for services from $209k a 188% increase from March 2016. Now Revenues for services in June 2017 are up to $943k vs 313k in June 2016 a 195% increase. Still showing solid growth.
Per CEO in last blog "Overall, this summer has been one of great progress and success with many exciting opportunities in the near future. Look for press releases soon on our upcoming clinic openings in Palm Beach and Dallas" , so 2 new clinics opening soon along with Kuwait which is currently under construction.
Kuwait opening by end of year per 10Q today,
"The US Stem Cell Clinic in Kuwait is currently under construction and is expected to open before the end of the year" page 25
Last 5 Quarters say it all, $USRM is building something here. With tides shifting and politics looking favorable I am guessing guidelines from the FDA in September will be even more beneficial to US Stel Cell's mission.
https://blogs.fda.gov/fdavoice/index.php/2017/07/how-fda-plans-to-help-consumers-capitalize-on-advances-in-science/
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k in Jun 2017 vs 443k last Jun 2016)
Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
336,461,515 shares issued and outstanding as of June 30, 2017 vs 327,613million last quarter. :)
Also, New Clinical trial completed and added July 20, 2017
Safety Analysis of Implantation of Stromal Vascular Fraction https://clinicaltrials.gov/ct2/show/NCT03226093?term=bioheart&rank=6
Enrollment: 676
Actual Study Start Date: January 1, 2015
Study Completion Date: June 1, 2017
Primary Completion Date: January 1, 2017 (Final data collection date for primary outcome measure)
WOW 676 enrolled.
Kristin released news about it in January but posted on Clinical trial site 2 weeks ago.
https://www.accesswire.com/453292/CSO-Kristin-Comella-Publishes-Paper-on-the-Implantation-of-Stromal-Vascular-Fraction-in-Patients-with-Degenerative-Disc-Disease
Trump just backed the right to try law!
http://dailysignal.com/2017/08/07/trump-backs-federal-right-to-try-law-already-enacted-in-37-states/
Also,
Phase 3 trial completion date changed to Feb 2019. Status set to active.
Us Stem Cell's MARVEL congestive heart failure Phase3 trial updated July 20, 2017
https://clinicaltrials.gov/archive/NCT00526253/2017_07_20
https://clinicaltrials.gov/archive/NCT00526253
$USRM
June was a record month for patients treated and stem cells banked, If that is the case we are looking at an even stronger month of growth for Q3,
"We have experienced continued success, growing patient satisfaction and clinic expansion, with June being a record month for number of patients treated and stem cells banked." per ceo in his last blog.
http://us-stemcell.com/ceo-blog-good-summer-at-ussc/
Wahoooooooooooo keep on growing and expanding. Thats all I care about. Hell I bought Tsla at 210 a few months back man do they sure lose a lot of money.
There are some parts of the quarterly which made me extremly happy I will post later. Cheers everyone
The US Stem Cell Clinic in Kuwait is currently under construction and is expected to open before the end of the year.
Record Revenues of $1.4 million for Q2. $2.5mil for Q1 & Q2, on track for a $6/7 mil rev year.
"With a new clinic in Miami, Florida and, as we intend, additional clinics opening soon around the country, management contends that American Stem Cell Centers of Excellence provides comprehensive stem cell treatments using the U.S. Stem Cell Inc. innovative technologies and the latest regenerative medicine research. U.S. Stem Cell’s team of scientists have pioneered these in-clinic regenerative medicine protocols and, in our estimation, have helped thousands of patients through their partly-owned subsidiary U.S. Stem Cell Clinic."
Just a few great snippets. Will post much more later.
Congrats everyone who's been buying :)
Well I added
Would love a mid day 10q
Nice opinion, the new completed study is nice too
New for a lot of people
The newly completed clinical trial with 676 enrolled was impressive. it was just updated July 20th
Also, New Clinical trial completed and added July 20, 2017
Safety Analysis of Implantation of Stromal Vascular Fraction https://clinicaltrials.gov/ct2/show/NCT03226093?term=bioheart&rank=6
Enrollment: 676
Actual Study Start Date: January 1, 2015
Study Completion Date: June 1, 2017
Primary Completion Date: January 1, 2017 (Final data collection date for primary outcome measure)
WOW 676 enrolled.
Kristin released news about it in January but posted on Clinical trial site 2 weeks ago.
https://www.accesswire.com/453292/CSO-Kristin-Comella-Publishes-Paper-on-the-Implantation-of-Stromal-Vascular-Fraction-in-Patients-with-Degenerative-Disc-Disease
Trump just backed the right to try law!
http://dailysignal.com/2017/08/07/trump-backs-federal-right-to-try-law-already-enacted-in-37-states/
Phase 3 trial completion date changed to Feb 2019. Status set to active.
Us Stem Cell's MARVEL congestive heart failure Phase3 trial updated July 20, 2017
https://clinicaltrials.gov/archive/NCT00526253/2017_07_20
https://clinicaltrials.gov/archive/NCT00526253
$USRM
Thats a fun thing before earnings. Coiled baby
Id say tomorrow
Aug 3rd http://www.politico.com/story/2017/08/03/senate-right-to-try-drug-bill-241293
Guys a boss
Add this with FDA guidelines out in september. Big money coming...
GM
Watch the RAAD presentation after reading Q2 financials ;)
Its real as day. Ortiz and Kristin made a good picture haha shes half his size. This will explode for athletes over the next few months. I have a feeling more and more pics will be coming up.
Will double down if earnings are great
They do first or second tuesday if were talking quarterly report. You're welcome.
Also Stem cell center of excellence uses $USRM serives and kits. Thanks for pointing that out. Appreciate it.
So this may be hard to understand but snything with Kristen relates to $USRM, cheers
$USRM article from last week about Kristen on COPD treatment with stem cells
http://communitynewspapers.com/south-miami/stem-cells-offer-new-solutions-for-lung-disease/
Could easily be $USRM http://www.vetbiologics.com/ (OWNED by USRM)